Coeptis Therapeutics, a biopharmaceutical company developing innovative cell therapy platforms for cancer, today announced the completion of its business combination with Bull Horn Holdings.
Coeptis public shares and warrants began trading today on the Nasdaq under the ticker symbols COEP and COEPW.
Bull Horn shareholders approved the deal last week, although approximately 88.5% of the SPAC’s remaining public shares were presented for redemption, leaving about $3.8 million in trust. Original deal terms called for Coeptis stakeholders to receive equity in Bull Horn valued at $175 million. Read more.
